ARCA Biopharma.

ARCA was founded on the belief that a precision medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of patients, can enable more effective therapies, improve patient outcomes and reduce healthcare costs.

Gencaro™ (bucindolol hydrochloride) is an investigational compound with potential as a treatment for atrial fibrillation in patients with heart failure. ARCA has identified genetic variations in cardiac receptors that we believe may predict individual patient response to Gencaro™, giving Gencaro™ the potential to be the first genetically-targeted cardiovascular therapeutic.